Source: PR Newswire

Press Release: MSK : Phase II Trial of Cadonilimab(PD-1/CTLA-4) Combination Regimen Launches in the United States for Perioperative Treatment of Gastric Cancer

HONG KONG, July 14, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that it has entered into a collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) to advance a Phase II clinical study evaluating a cadonilimab-based combination regimen...

Read full article »
Est. Annual Revenue
$5.0-10B
Est. Employees
10-50K
Selwyn Vickers's photo - President & CEO of MSK

President & CEO

Selwyn Vickers

CEO Approval Rating

45/100

Read more